Ketryx, the agentic continuous compliance platform for safety-critical product development, announced that William A. Hawkins, former Chairman and CEO of Medtronic, has joined its Board of Directors and participated in the company's Series B financing. This strategic move underscores the growing importance of AI-driven compliance solutions in life sciences and other regulated industries.
Ketryx helps companies in safety-critical industries, including medical devices, pharmaceuticals, and robotics, accelerate product development by automatically generating compliant documentation, maintaining continuous traceability, and enabling safe and verifiable AI at scale in the tools teams already use. The platform overlays existing tools to automate documentation, create traceability, and accelerate release cycles without disrupting workflows. According to the company, its AI agents reduce manual work by up to 90 percent and help teams identify and close compliance gaps.
Hawkins brings decades of leadership experience from Medtronic, where he served as Chairman and CEO from 2007 to 2011, navigating the company through significant growth and regulatory challenges. His expertise is expected to guide Ketryx as it expands its footprint in life sciences. The participation in Series B financing further aligns Hawkins with Ketryx's mission to solve what the company calls the 'AI bottleneck' in regulated product development.
For more information, visit www.ketryx.com.
